Brainstorm Cell Therapeutics (BCLI) Reports Expanded Manufacturing of NurOwn for Phase 2 Progressive MS Trial
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced today that it has expanded its autologous cell manufacturing capacity to produce NurOwn® ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)